AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment for TGCT Positive Proof-of-Concept Results...
Disability
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis MoonLake announces...
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
Results highlight a potential novel treatment for diabetic and other retinopathiesUnique Wnt-mediated mechanism increases vascular integrity, and transforms pathologic regrowth...
GNT Pharma Provides Update on Two Phase III Studies of Nelonemdaz for Acute Ischemic Stroke Patients Treated with tPA (ENIS-3) or Endovascular Thrombectomy (RODIN)
Promising efficacy and safety profiles were observed in prior Phase II studies in acute ischemic stroke patients treated with recanalization...
Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
WASHINGTON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute today announced it is receiving an additional $21.8 million...
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new...
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
German Federal Social Court Schedules Hearing on Classification of Exoskeleton Medical Devices for Spinal Cord Injured Individuals
MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq: RWLK) ("ReWalk"...
AmMax Bio Announces Presentation of Phase 2 PK/PD Data of ABM-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) at ESMO Congress 2022
Unique, intra-articular administration of AMB-05X yielded sustained, high synovial concentrations with low systemic exposures and positive clinical efficacyREDWOOD CITY, Calif.,...
Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa...
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders
Bagsværd, Denmark and Watertown, Mass, US, 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today...
TG Therapeutics Announces Results from the ULTIMATE I & II Phase 3 Trials of Investigational Ublituximab in RMS Published in The New England Journal of Medicine
Ublituximab is an investigational targeted B-cell therapy that shows superior efficacy when compared with teriflunomide, a commonly prescribed oral treatment...
Todos Medical Reports Second Quarter 2022 Financial Results and Business Update Conference Call on Tuesday, August 23 at 8:30am ET
Preparations for Tollovir™ Phase 2 Trial Extension to Support EUA Filing Now Complete Preparations for Tollovid™ Phase 2 Trial in...
180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder
PALO ALTO, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets
World first study utilizing Somalogic SomaScan® assay# to assess up to 7,000 plasma proteins in Long COVID-19 patients has elucidated...
Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID
Results from Planned Interim Analysis Expected First Half 2023 Long COVID Afflicts More Than 30% of Patients Following Infection with...
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis
YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease
Orphan designation provides potential for up to 10-year market exclusivity in the EU upon regulatory approvalGENEVA, Switzerland and NEWTON, Mass.,...